Ketamine for Major Depressive Disorder

Status unconfirmed · Phase 1 · Has a placebo group

Conditions studied: Major Depressive Disorder

In brief

The purpose of this study is to measure the amount of ketamine in blood over time in subjects diagnosed with Major Depressive Disorder (MDD) and explore the anti-depressive effects of ketamine delivered by transdermal patch.

Key facts

Study ID
NCT03721900
Run by
Shenox Pharmaceuticals, LLC
People needed
14
Starts
2018-12-28
Expected to finish
2019-06-06
Last updated by the study team
2019-04-25

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.